HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetic Regs Would Be Codified As One Directive Under EU Proposal

This article was originally published in The Rose Sheet

Executive Summary

The European Commission will consolidate approximately 45 directives covering cosmetics into one in 2007 as part of an overall effort to reduce the volume of EU legislation

You may also be interested in...



European Commission goals

Developing a proposal to simplify cosmetics legislation "for business competitiveness and better consumer safety" is one priority for the EU's Enterprise Directorate General in 2005, the agency says in a goals and activities document released Sept. 3. "This is an area where a large body of legislation has accumulated as a result of successive acts dealing with specific issues," Enterprise DG notes. The agency plans to conduct an "analysis of the competitive position of the sector...[which] will help to define the appropriate framework" for cosmetics legislation. Other priorities include implementation of the REACH chemicals program...

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

MADIT-CRT Data Support Expanded Cardiac Resynchronization Market

The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel